Vulvar/Vaginal Squamous Cell Carcinoma
Associated Genetic Biomarkers
Vulvar/vaginal squamous cell carcinomas most frequently harbor alterations in TP53, CDKN2A, PIK3CA, NOTCH1, and KMT2D .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, CDKN2A Mutation, and PIK3CA Mutation are the most common alterations in vulvar/vaginal squamous cell carcinoma .
There are 2 clinical trials for vulvar/vaginal squamous cell carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain vulvar/vaginal squamous cell carcinoma as an inclusion criterion, 2 are phase 2 (2 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for vulvar/vaginal squamous cell carcinoma clinical trials .
Atezolizumab, avelumab, and stereotactic body radiation therapy are the most common interventions in vulvar/vaginal squamous cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.